$52.94
-0.61[-1.14%]
Last update: 10:07AM Get Real Time Here
Arcellx
(NASDAQ:ACLX)Latest News for Arcellx Stock (NASDAQ:ACLX)
Arcellx Stock (NASDAQ: ACLX)
Categories: All
Monday, April 15, 2024
Thursday, April 11, 2024
Monday, March 18, 2024
Thursday, March 14, 2024
Thursday, March 07, 2024
- Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan StanleyVandana Singh - Mar 7, 2024, 2:52PM
- Morgan Stanley Initiates Coverage On Arcellx with Overweight Rating, Announces Price Target of $81Benzinga Newsdesk - Mar 7, 2024, 3:56AM
Tuesday, March 05, 2024
Thursday, February 29, 2024
- HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $82Benzinga Newsdesk - Feb 29, 2024, 3:28PM
- On Wednesday February 28, 2024, Arcellx Reported Q4 EPS $0.42 Up From $(0.76) YoY, Sales $63.15MHappy Mohamed - Feb 29, 2024, 3:28PM
- Canaccord Genuity Maintains Buy on Arcellx, Raises Price Target to $85Benzinga Newsdesk - Feb 29, 2024, 9:56AM
- Barclays Maintains Overweight on Arcellx, Raises Price Target to $73Benzinga Newsdesk - Feb 29, 2024, 9:05AM
- Arcellx Analysts Boost Their Forecasts After Q4 ResultsAvi Kapoor - Feb 29, 2024, 8:03AM
- Needham Maintains Buy on Arcellx, Raises Price Target to $72Benzinga Newsdesk - Feb 29, 2024, 7:51AM
- Baird Maintains Outperform on Arcellx, Raises Price Target to $77Benzinga Newsdesk - Feb 29, 2024, 7:14AM
Wednesday, February 28, 2024
Thursday, January 04, 2024
- Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024Vandana Singh - Jan 4, 2024, 2:08PM
- Needham Maintains Buy Rating for Arcellx: Here's What You Need To KnowBenzinga Insights - Jan 4, 2024, 12:00PM
- Needham Maintains Buy on Arcellx, Raises Price Target to $71Benzinga Newsdesk - Jan 4, 2024, 6:15AM
Tuesday, December 19, 2023
- Arcellx shares are trading higher after Scotiabank initiated coverage on the stock with a Sector Outperform rating and announced a $66 price target.Benzinga Newsdesk - Dec 19, 2023, 11:38AM
- Scotiabank Initiates Coverage On Arcellx with Sector Outperform Rating, Announces Price Target of $66Benzinga Newsdesk - Dec 19, 2023, 11:29AM
Tuesday, December 12, 2023
Monday, December 11, 2023
Friday, December 08, 2023
Wednesday, November 15, 2023
- HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $60Benzinga Newsdesk - Nov 15, 2023, 1:48PM
- Needham Maintains Buy on Arcellx, Raises Price Target to $60Benzinga Newsdesk - Nov 15, 2023, 1:34PM
- Kite, A Gilead Company, And Arcellx Have Expanded Their Existing Collaboration, Which Was Originally Announced In December 2022, For CART-ddBCMA To Include Lymphomas; Arcellx To Receive $200M Equity Investment And $85M Upfront Cash PaymentBenzinga Newsdesk - Nov 15, 2023, 6:03AM
Monday, November 13, 2023
Thursday, November 02, 2023
- Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Nov 2, 2023, 2:26PM
- Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?Vandana Singh - Nov 2, 2023, 12:39PM
- Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On ThursdayLisa Levin - Nov 2, 2023, 11:01AM
Monday, October 30, 2023
Tuesday, October 17, 2023
Tuesday, August 15, 2023
- Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic PotentialVandana Singh - Aug 15, 2023, 2:42PM
- FDA Gives Green Signal To Arcellx's Stopped Blood Cancer StudyVandana Singh - Aug 15, 2023, 9:05AM
- Baird Maintains Outperform on Arcellx, Raises Price Target to $52Benzinga Newsdesk - Aug 15, 2023, 8:57AM
- Stifel Maintains Buy on Arcellx, Lowers Price Target to $52Benzinga Newsdesk - Aug 15, 2023, 8:33AM
- Needham Reinstates Buy on Arcellx, Maintains $51 Price TargetBenzinga Newsdesk - Aug 15, 2023, 7:18AM
- HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $50Benzinga Newsdesk - Aug 15, 2023, 6:43AM
Monday, August 14, 2023
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga Insights - Aug 14, 2023, 5:32PM
- Arcellx Q2 EPS $(0.50) Misses $(0.31) Estimate, Sales $14.30M Miss $40.55M EstimateBenzinga Newsdesk - Aug 14, 2023, 4:38PM
- Arcellx Announced The FDA Has Lifted The Partial Clinical Hold Placed On CART-ddBCMA investigational New Drug For The Treatment Of Patients With Relapsed Or Refractory Multiple MyelomaBenzinga Newsdesk - Aug 14, 2023, 4:36PM